v
Search
Advanced

Publications > Journals > Most Viewed Articles

Results per page:
v
Original Article Open Access
Xiaobin Chi, Zerun Lin, Zhijian Chen, Jianda Yu, Yongbiao Chen, Honghuan Lin, Qiucheng Cai, Lizhi Lv
Published online February 5, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 4176
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2025.00571
Abstract
Hepatic ischemia–reperfusion (HIR) injury impairs outcomes post–liver transplantation. Therefore, we aimed to investigate the role and mechanism of miR-381-3p in HIR. The [...] Read more.

Hepatic ischemia–reperfusion (HIR) injury impairs outcomes post–liver transplantation. Therefore, we aimed to investigate the role and mechanism of miR-381-3p in HIR.

The study enrolled 150 healthy controls, 82 non-HIR-injured patients, and 68 patients with HIR injury following liver transplantation. Clinical data were analyzed. Multivariate analysis identified HIR risk factors; the predictive value of miR-381-3p was assessed via receiver operating characteristic analysis. An in vitro hypoxia/reoxygenation (H/R) model was established and employed. The cellular effects of miR-381-3p and JAK2 were evaluated using CCK-8, flow cytometry, ELISA, luciferase, RIP, and bioinformatics.

Serum miR-381-3p was significantly elevated in HIR compared with the other groups. miR-381-3p was the strongest independent HIR risk factor, which was confirmed by receiver operating characteristic analysis. H/R upregulated miR-381-3p. Inhibiting miR-381-3p counteracted H/R-induced decreased viability and increased apoptosis, inflammation, and oxidative stress. miR-381-3p directly bound to and suppressed JAK2 via its 3′ untranslated region (validated by luciferase and RIP). Transfection of si-JAK2 abolished the protective effects of miR-381-3p inhibition.

miR-381-3p exacerbates post-transplant HIR by directly targeting JAK2, amplifying inflammation and oxidative stress. Thus, our findings nominate serum miR-381-3p as a promising non-invasive biomarker and suggest its potential as a therapeutic target for mitigating HIR injury.

Full article
Review Article Open Access
Ying He, Danni Zhu, Yuwei Zeng, Jienv Lou, Dan Mao
Published online June 29, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 4172
Neurosurgical Subspecialties. doi:10.14218/NSSS.2026.00005
Abstract
Brain tumors represent a common class of life-threatening neoplastic conditions. The core objective of neurosurgery is to achieve maximal safe resection of tumors while preserving [...] Read more.

Brain tumors represent a common class of life-threatening neoplastic conditions. The core objective of neurosurgery is to achieve maximal safe resection of tumors while preserving the patient’s neurological function. Intraoperative ultrasound (IOUS) assists surgeons in achieving complete lesion removal, helping to avoid insufficient resection or excessive excision of normal tissue, thereby reducing surgical morbidity. Contrast-enhanced ultrasound (CEUS), through harmonic imaging, enables more precise localization of lesions and intracranial structures. This review focuses on the synergistic value of IOUS and CEUS in brain tumor surgery. It traces the technological evolution from two-dimensional ultrasound to elastography, color Doppler flow imaging, microvascular flow imaging, artificial intelligence, and beyond, with an emphasis on CEUS for cranial tumors. It also examines the clinical applications of IOUS and CEUS in precise resection, residual tumor identification, vascular protection, boundary differentiation from peritumoral edema, and prognostic assessment. The review concludes by summarizing diagnostic performance, current limitations, and future directions, offering neurosurgeons a theoretical and practical framework for optimizing intraoperative guidance.

Full article
Original Article Open Access
Hao Wang, Zhiquan Xu, Ziqi Zhang, Yan You, Ranning Xu, Hongli Chen, Hongshuai Cui, Xiaoyong Luo, Rui Liao
Published online April 10, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 4071
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2025.00616
Abstract
The immunosuppressive tumor microenvironment (TME) limits immunotherapy efficacy in intrahepatic cholangiocarcinoma (ICC). Understanding the molecular drivers of this TME is essential [...] Read more.

The immunosuppressive tumor microenvironment (TME) limits immunotherapy efficacy in intrahepatic cholangiocarcinoma (ICC). Understanding the molecular drivers of this TME is essential for developing new therapies. This study aimed to identify novel oncogenes that modulate the immune landscape of ICC using a multi-omics approach.

We integrated transcriptomic and proteomic data from our ICC cohorts with public datasets (TCGA-CHOL, GSE107943, OEP002768) to identify genes co-upregulated with PD-L1 (CD274). Single-cell RNA sequencing (scRNA-seq) was used to analyze cell-type-specific expression and intercellular communication. Clinical significance was validated through tissue microarrays and multiplex immunofluorescence in an independent ICC cohort.

Multi-omics screening identified TACC3 as a key candidate in ICC. Elevated TACC3 expression in ICC tissues correlated with poor prognosis and promoted tumor cell proliferation and migration. TACC3 activated the STAT3 pathway, increasing PD-L1 transcription. scRNA-seq showed TACC3/PD-L1 interaction in malignant epithelial cells, with PD-L1 co-expressed with FOXP3 in regulatory T cells (Tregs). Cell–cell communication analysis predicted strong interactions between malignant cells and Tregs. TACC3 knockdown reduced PD-L1 expression and inhibited STAT3 and AKT phosphorylation. Clinical validation confirmed co-expression of TACC3, PD-L1, and FOXP3, with high TACC3 levels linked to worse clinicopathological features and shorter progression-free survival.

Our study defines a TACC3-STAT3-PD-L1 axis driving immunosuppression in ICC. TACC3 fosters an immunosuppressive TME by upregulating PD-L1 and is associated with a Treg-rich contexture, suggesting that TACC3 may serve as a potential therapeutic target to overcome ICC immunosuppression.

Full article
Original Article Open Access
Sophia Voronova, Maria Bograya, Anastasia Koshel, Vladimir Malashchenko, Maria Vulf, Maria Beletskaya, Larisa Litvinova
Published online April 25, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 4068
Gene Expression. doi:10.14218/GE.2025.00088
Abstract
Mitochondrial DNA (mtDNA) variability, especially heteroplasmy, is believed to affect cellular immunobiogenesis, particularly in monocytes in metabolic syndrome (MetS). This study [...] Read more.

Mitochondrial DNA (mtDNA) variability, especially heteroplasmy, is believed to affect cellular immunobiogenesis, particularly in monocytes in metabolic syndrome (MetS). This study aimed to identify associations of monocytic mtDNA variability with its phenotypic indices, including cytokine secretion and gene expression, and cardiometabolic parameters in patients with MetS.

The cross-sectional study recruited 87 adult participants, including 34 healthy blood donors (Control group), 21 obese patients (Obesity group), and 32 MetS patients (MetS group). Blood biochemistry tests were performed on venous blood samples, and monocytes (CD14+ cells) were isolated. Monocyte mtDNA was analyzed by next-generation sequencing to identify low (5–10%) and intermediate (10–95%) heteroplasmy, and homoplasmy (≥95%). Expression of genes related to mitochondrial biogenesis, mitochondrial uncoupling, oxidative stress system, and NF-κB signaling was assessed by quantitative real-time polymerase chain reaction. Monocytes cultured with and without lipopolysaccharide for 24 h were analyzed by enzyme-linked immunosorbent assay to assess the cytokine secretion stimulation index.

Monocyte mtDNA showed low variability, but alternative homoplasmies were significantly more common. Intermediate and low heteroplasmy from the protein-coding locus correlated with stenosis (r = 0.396; 95% confidence interval (CI) 0.067–0.647) and low-density lipoprotein levels (r = −0.258; 95% CI −0.45 – −0.043). Intermediate heteroplasmy from the rRNA locus correlated with blood insulin levels (r = −0.228; 95% CI −0.424 – −0.019). D-loop low heteroplasmy correlated with fasting blood glucose (r = 0.275; 95% CI 0.062–0.464). Homoplasmies were associated with creatinine, blood urea nitrogen, and alkaline phosphatase. Intermediate heteroplasmy in mtDNA was associated with the monocyte cytokine secretion stimulation index (R2 = 0.156, P = 0.003). However, there was no significant association between mtDNA variability and the expression of the various genes.

Monocyte mtDNA shows relatively low variability. Low and Intermediate heteroplasmy are associated with cardiometabolic parameters, and intermediate heteroplasmy is associated with the monocyte cytokine secretion stimulation index.

Full article
Review Article Open Access
Moein Sabounchi, Bomi Kim, Ankit Sakhuja
Published online June 15, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 4056
Journal of Translational Critical Care Medicine. doi:10.14218/JTCCM.2025.00023
Abstract
Critical care medicine requires rapid, high-stakes decisions informed by dynamic and complex streams of patient data. Traditional predictive models have shown value in forecasting [...] Read more.

Critical care medicine requires rapid, high-stakes decisions informed by dynamic and complex streams of patient data. Traditional predictive models have shown value in forecasting deterioration and identifying subphenotypes. However, this leaves a critical gap between anticipating adverse outcomes and guiding therapeutic interventions. Achieving true personalization demands moving beyond generalized protocols toward individualized strategies that account for patient heterogeneity and consequences of alternative clinical actions. Emerging methods in prescriptive artificial intelligence, particularly causal machine learning (causal ML) and reinforcement learning (RL), are beginning to bridge this gap. Causal ML enables estimation of individualized treatment effects by addressing confounding and enabling counterfactual reasoning, allowing clinicians to ask whether a specific intervention is likely to help or harm a given patient. RL can generate adaptive treatment policies that evolve with patient state. The objective of this review is to examine how critical care can progress from generalized prediction to true personalization through the development of prescriptive artificial intelligence. The review contributes by (1) surveying the achievements and limitations of current predictive models, (2) detailing how causal ML and RL can generate individualized treatment effects and sequential decision strategies, (3) identifying the major translational, technical, clinical, ethical, and regulatory barriers to implementation, and (4) outlining future pathways such as digital twins and clinician in the loop systems that may enable safe and actionable personalized decision support at the bedside.

Full article
Research Letter Open Access
Angels Barberà, Juan González, Montserrat Martin, Pedro Luis Fernández, Albert Oriol, Fina Martínez-Soler, Tomas Santalucia, Jose Luis Mate
Published online March 18, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 4056
Journal of Clinical and Translational Pathology. doi:10.14218/JCTP.2025.00038
Original Article Open Access
Han Zhao, Yansheng Liu, Yingmei Tang, Ningning Wang, Yanmin Liu, Yiling Li, Chunyang Huang, Jieting Duan, Yan Feng, Linhua Zheng, Ruiqing Sun, Xiufang Wang, Juan Deng, Gui Jia, Patrick S.C. Leung, M. Eric Gershwin, Yulong Shang, Ying Han
Published online May 15, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 3990
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00082
Abstract
The current criterion of biochemical response to ursodeoxycholic acid in primary biliary cholangitis is an alkaline phosphatase (ALP) level of ≤1.67 × the upper limit of normal [...] Read more.

The current criterion of biochemical response to ursodeoxycholic acid in primary biliary cholangitis is an alkaline phosphatase (ALP) level of ≤1.67 × the upper limit of normal (ULN) after 12 months of treatment. However, a proportion of patients who meet this parameter may still progress to liver decompensation. This study aimed to optimize the clinical management of primary biliary cholangitis by (1) establishing ALP normalization as a core treatment target, (2) identifying early intervention windows, and (3) developing risk stratification criteria.

This multicenter retrospective study included an internal cohort and an external validation cohort. We assessed the prognostic impact of ALP normalization with Kaplan-Meier and Cox regression. Sankey diagrams and segmented Poisson regression analysis mapped dynamic risk transitions to identify critical intervention windows. Predictive performance (sensitivity/specificity/positive predictive value/negative predictive value [NPV]) of Mayo, Paris II, and Toronto criteria for 12-month ALP normalization was compared.

Patients achieving ALP normalization showed significantly higher complication-free survival versus those with ALP 1.0–1.67 × ULN (89.8% vs. 79.8%; P = 0.016). Segmented Poisson regression identified significant change points at 3.73 and 5.5 months for high-to-medium and medium-to-low risk transitions, respectively. Failure to meet the Toronto criteria at month 3 predicted non-normalization with 95% NPV, whereas Paris II criteria at month 6 provided optimal specificity (73%) for identifying patients who failed to achieve ALP normalization.

ALP normalization significantly improves clinical outcomes. Two subgroups demonstrate low normalization probability and warrant early intervention: (1) patients with ALP ≥ 1.67 × ULN after 3 months and (2) those not meeting Paris II criteria by month 6.

Full article
Research Letter Open Access
Jinyan Chen, Ruijie Zhao, Chiyu He, Huigang Li, Yajie You, Zuyuan Lin, Ze Xiang, Jianyong Zhuo, Wei Shen, Zhihang Hu, Shusen Zheng, Xiao Xu, Di Lu
Published online December 18, 2025
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 3984
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2025.00238
Review Article Open Access
Yang Wang, Zhaoshen Li, Xiangyu Kong
Published online June 26, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 3969
Cancer Screening and Prevention. doi:10.14218/CSP.2026.00033
Abstract
Gastrointestinal (GI) cancers account for approximately one-third of annual cancer-related deaths globally, while outcomes remain poor despite advances in surgery, chemotherapy, [...] Read more.

Gastrointestinal (GI) cancers account for approximately one-third of annual cancer-related deaths globally, while outcomes remain poor despite advances in surgery, chemotherapy, radiotherapy, and immunotherapy. Given the challenges of persistent resistance and treatment-related toxicities in current therapies, the role of the gut microbiota and the potential role of fecal microbiota transplantation (FMT) in GI cancer therapy are receiving increasing attention. This review aims to explore the potential and mechanisms of FMT as a therapeutic adjuvant in the treatment of GI cancers. Microbiome studies suggest that FMT might influence antitumor treatment efficacy and treatment-related toxicity through three proposed pathways, including enhancing antigen presentation, reshaping the tumor microenvironment, and preserving intestinal barrier function. Preliminary clinical studies of FMT combined with immune checkpoint inhibitors, chemotherapy, or radiotherapy have reported response signals, and selected studies and case reports have described improvements in treatment-related intestinal toxicities. However, these observations do not establish that the outcomes were attributable to FMT. Clinical application is also hindered by donor microbiota functional heterogeneity, substantial interindividual variability in engraftment, and the absence of validated predictive models. We also propose an unvalidated, hypothesis-generating functional screening framework: the Healthy Donor-derived Microbiota Xenograft model as a preclinical functional screening platform and the proposed Xenograft-screened FMT concept for future clinical evaluation, which links donor-level functional evaluation with model-informed candidate donor selection. By integrating mechanistic insights, emerging preclinical and clinical evidence, and a functional screening framework, this review presents a testable concept for future evaluation and offers insights into future clinical investigation of FMT as a therapeutic approach in GI oncology.

Full article
Original Article Open Access
Yiping Dai, Yao Zhu, Chang Hu, Hui Chen, Zhiyong Peng, Yiming Li
Published online June 29, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 3967
Journal of Translational Critical Care Medicine. doi:10.14218/JTCCM.2026.00004
Abstract
While norepinephrine (NE) is the cornerstone of septic shock resuscitation, “macrocirculation–microcirculation decoupling” at high doses remains a critical clinical challenge. This [...] Read more.

While norepinephrine (NE) is the cornerstone of septic shock resuscitation, “macrocirculation–microcirculation decoupling” at high doses remains a critical clinical challenge. This study aimed to explore the quantitative tipping point where the NE dose shifts from a life-saving vasopressor to a microcirculatory toxin in septic intensive care unit patients.

In this prospective observational study (January–September 2025), we used handheld vital microscopy to monitor sublingual microcirculation (microvascular flow index [MFI], total vessel density, perfused vessel density, proportion of perfused vessels [PPV], and heterogeneity index [HI]) in adult septic patients within 24 hours of admission and on Day 3. Beyond standard linear analysis, generalized additive models were employed to identify the dose–response thresholds associated with microcirculatory deterioration, adjusted for Acute Physiology and Chronic Health Evaluation II, interleukin-6, and systemic hemodynamics.

Of 144 screened patients, 66 were analyzed. The NE dose showed strong linear correlations with lactate (r = 0.583, P < 0.001) and HI (r = 0.444, P < 0.001), and negative correlations with MFI (r = −0.492, P < 0.001). Crucially, generalized additive models analysis revealed a significant nonlinear “cliff effect”: when the NE dose exceeds the 0.71–0.80 µg/kg/min threshold (PPV: 0.71 µg/kg/min, HI: 0.72 µg/kg/min, MFI: 0.80 µg/kg/min), microcirculatory perfusion parameters deteriorate abruptly (all P < 0.05). Multivariable Cox regression identified an NE dose of 0.80 µg/kg/min as an independent predictor of increased mortality (hazard ratio = 1.32, 95% confidence interval: 1.28–3.10, P = 0.039).

In patients with septic shock, higher NE doses were associated with impaired microcirculatory perfusion and worse outcomes. These findings support individualized vasopressor titration and suggest that microcirculatory monitoring may help identify patients at risk of vasopressor-associated microvascular dysfunction.

Full article
PrevPage 18 of 36 12…171819…3536Next
Back to Top